OA03-RF01.03. Non-Cisplatin-Based Preoperative Chemotherapy for Cisplatin-Unfit Esophageal Cancer: A Multicenter Retrospective Study in Japan

Clicks: 18
ID: 326120
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #339 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background Although cisplatin-based neoadjuvant chemotherapy is the standard for resectable esophageal squamous cell carcinoma in Japan, some patients are unfit due to age, renal, or cardiac dysfunction. No established treatment option exists for cisplatin-unfit patients. We compared the efficacy between non-cisplatin-based preoperative chemotherapy (noCDDP) followed by surgery and surgery alone (Sx). Methods This multicenter retrospective study included patients from 25 institutions in the Young Investigators’ Group of Japan Esophageal Oncology Group. Patients treated with noCDDP or Sx between 2017 and 2021 were included if they had resectable thoracic esophageal squamous cell carcinoma, ECOG PS 0–2, and were considered unfit for cisplatin due to advanced age (≥75 years), renal dysfunction (creatinine clearance 20–59 mL/min), or cardiac dysfunction (ejection fraction <50%, heart failure history, or uncontrolled arrhythmia). Overall survival (OS) and progression-free survival (PFS) were analyzed using Kaplan–Meier estimates, log-rank tests, and Cox proportional hazards models. To adjust for baseline imbalances, inverse probability of treatment weighting (IPTW) was applied using clinical covariates including age, sex, ECOG PS, body mass index, creatinine clearance, hemoglobin, neutrophil–lymphocyte ratio, cardiac dysfunction, tumor location, and cT, cN, cM factors. Results A total of 298 patients were included (noCDDP, n=80; Sx, n=218). Preoperative therapy in the noCDDP group consisted of nedaplatin + fluorouracil therapy (46%), fluorouracil, levofolinate plus oxaliplatin (FOLFOX) therapy (42%), and fluorouracil, levoflinate, oxaliplatin plus docetaxel (FLOT) therapy (11%). After IPTW, baseline characteristics were well balanced between groups. The 1-year/3-year PFS rates were 73%/62% in the noCDDP group and 70%/56% in the Sx group (hazard ratio [HR] 0.99, 95% confidence interval [CI] 0.60–1.64, p=0.98). The 1-year/3-year OS rates were 84%/67% and 85%/62%, respectively (HR 0.84, 95% CI 0.53–1.33, p=0.45). No significant survival difference was observed. Conclusion In cisplatin-unfit patients with resectable esophageal squamous cell carcinoma, non-cisplatin-based preoperative chemotherapy did not improve survival compared with surgery alone after adjustment for confounding factors. These findings do not support a clear survival benefit of routine use of noCDDP regimens in this population Prospective studies are warranted to identify subgroups that could benefit from preoperative treatment and to establish optimal therapeutic strategies for cisplatin-unsuitable patients.
Reference Key
openalex_W7204010155 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yasunobu Ishizuka, Toru Kadono, Akitoshi Hakoda, Shun Yamamoto, Taisuke Hosokai, Motoo Nomura, Masahiro Fukuoka, Takeshi Yamashita, Kunihiro Fushiki, Kazuhiro Shiraishi, Yuta Sato, Kohei Kanamori, Yohei Ozawa, Atsushi Takeno, Masaaki Iwatsuki, Yuta Itohki, Yusuke Amanuma, Kazuma Sato, Ryoma Haneda, Hisahiro Matsubara, Takeo Bamba, Hiroki Hiratsuka, Naoshi Fujiwara, Takashi Ogata, Yoshito Komatsu, Hiroshi Ichikawa, Takashi Ohta, Hiroaki Nagano, Hiroya Takeuchi, Ken Kato
Are you one of these authors? Claim your profile
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.022
URL
https://doi.org/10.1093/dote/doag077.022
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.